Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...